2-(3-Aminopropoxy)propan-2-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(3-Aminopropoxy)propan-2-ol
• 英文别名: 2-(3-aminopropoxy)propan-2-ol
• 化学式: C₆H₁₅NO₂
• 分子量: 133.19
• InChiKey: BTRCWWAHBUYREV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UNIV OSLO

  公开号：WO2018033719A1

  公开（公告）日：2018-02-22

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  该发明提供了一种化合物，用于治疗和/或预防人类或非人哺乳动物体内的细菌感染，所述方法包括将该化合物与β-内酰胺类抗生素（可以同时、分开或顺序地）结合给药，其中所述化合物具有一般式I：（I）（其中：Q是一个亲脂性、选择性结合Zn2+离子的基团，包括至少一个，最好是两个或更多（例如2、3或4个），可选择地取代的不饱和杂环环，例如5或6元杂环环（这些环最好包括至少一个从N、S和O中选择的杂原子，最好是N）；其中任何可选择的取代基可以选择自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个L，可以相同也可以不同，是一个共价键或一个连接基；每个W，可以相同也可以不同，是一个非肽性亲水基团，包括一个或多个羟基；x是1到3之间的整数）或其立体异构体、药学上可接受的盐或前药。
• NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
  申请人：Arbutus Biopharma Corporation

  公开号：EP3238738A1

  公开（公告）日：2017-11-01

  The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV))

  本发明提供的脂质可用于脂质微粒中，有利于向细胞体内输送治疗剂。特别是，本发明提供了具有以下结构的脂质：式(I)或(XXXV))
• Compounds
  申请人：UNIVERSITETET I OSLO

  公开号：US10961223B2

  公开（公告）日：2021-03-30

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  本发明提供了用于治疗和/或预防人类或非人类哺乳动物细菌感染的方法的化合物，所述方法包括将所述化合物与β-内酰胺类抗生素（同时、分别或依次）联合给药，其中所述化合物具有通式I： (I) (其中：Q 是对 Zn2+ 离子有选择性的亲脂性锌螯合基团，它包括至少一个，最好是两个或更多 （例如 2、3 或 4 个）任选取代的不饱和杂环，例如5或6元杂环（此类环最好包括至少一个选自N、S和O的杂原子，最好是N）；其中任选取代基可选自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个 L（可以相同或不同）是共价键或连接体；每个 W（可以相同或不同）是非肽亲水基团，包括一个或多个羟基；以及 x 是 1 至 3 的整数）或其立体异构体、药学上可接受的盐或原药。
• ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION
  申请人：Universitetet I Oslo

  公开号：EP3497095B1

  公开（公告）日：2021-07-14
• COMPOUNDS
  申请人：UNIVERSITETET I OSLO

  公开号：US20190284167A1

  公开（公告）日：2019-09-19

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn 2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.